Aptevo Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $1.91M
- P/E (TTM)
- –
- Dividend yield
- –
About Aptevo Therapeutics
Pharmaceutical Preparations, SIC 2834
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and development of novel immunotherapy candidates for the treatment of various cancers. The company leverages its proprietary ADAPTIR and ADAPTIR-FLEX protein technology platforms to engineer monospecific and multi-specific antibody-based therapeutics designed to harness the immune system against cancer cells. Its pipeline includes clinical candidates such as mipletamig, a CD123xCD3 T cell engager targeting acute myeloid leukemia, and ALG.APV-527, a bispecific molecule targeting 4-1BB and 5T4 developed for solid tumors, alongside several preclinical programs.
The company conducts its operations in the United States and maintains partnerships, including a clinical collaboration with Alligator Bioscience AB for solid tumor drug development. Aptevo maintains its principal executive offices and headquarters in Seattle, Washington.
Summary of the business section of Aptevo Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aptevo Therapeutics Inc.
- Headquarters
- Seattle, WA
- Address
- 2401 4th Ave., Suite 1050 98121
- Phone
- (206) 838-0500
- Employees
- 40, Dec 31, 2023
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Seattle, WA
Stock & identifiers
- Ticker
- APVO
- Exchange
- Nasdaq
- Shares outstanding
- 2M, Aug 14, 2026
- Public float
- $9.80M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-18 reverse, Mar 26, 2026; 1-for-18 reverse, Dec 30, 2025; 1-for-20 reverse, May 27, 2025; 1-for-37 reverse, Dec 4, 2024; 1-for-37 reverse, Dec 2, 2024; 1-for-44 reverse, Mar 6, 2024; 1-for-17.5 reverse, May 13, 2020; 1-for-14 reverse, Mar 27, 2020
- SEC CIK
- 1671584
- CUSIP
- 03835L702
- ISIN
- US03835L7029
- LEI
- 529900UTQOXOZBMZFN24
- EIN
- 81-1567056
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jeffrey G. Lamothe | President and CEO, Director | 961 |
| Marvin L. White | Executive Chair, Director | 1,667 |
| Daphne Taylor | SVP, CFO | 638 |
| Dirk Huebner | SVP, CMO | 638 |
| SoYoung Kwon | SVP, GC, BD & Corp Affairs | 638 |
| Mary Jo Janatpour | SVP, CSO | 0 |
| Daniel Abdun-Nabi | Director | 400 |
| Barbara Lopez Kunz | Director | 400 |
| John Niederhuber | Director | 400 |
| Grady Grant III | Director | 1,150 |
| Zsolt Harsanyi | Director | 400 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.27M | $1.28M | $952.57K | $0 | – |
| FY2024 | $846.34K | $837.49K | $690.85K | $0 | – |
| FY2023 | $916.40K | $809.96K | $663.41K | $0 | – |
| FY2022 | $1.17M | $786.51K | $859.76K | $6 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“Aptevo employed 40 full-time persons as of December 31, 2023.”
Corporate history
Events identified from SEC filings